Results 181 to 190 of about 125,477 (319)

Exploring Autophagy Inducing Molecules: Targeting Diverse Pathways in Alzheimer's Disease Management

Medicinal Research Reviews, Volume 46, Issue 1, Page 272-298, January 2026.
ABSTRACT Neurodegenerative disorders, including Alzheimer's disease (AD), impose a significant burden on society due to their progressive nature and the associated healthcare costs. Autophagy, a vital cellular degradation process, has emerged as a promising therapeutic target in these disorders.
Baljinder Singh, Shubham Mahajan, Sadikalmahdi Abdella, Rehan Khan, Sanjay Garg   +4 more
wiley   +1 more source

Basic Science and Pathogenesis. [PDF]

Alzheimers Dement
Carare ROO.
europepmc   +1 more source

Activity‐restoring mutations in the histamine H3 receptor increase constitutive activity and reduce structural stability

Protein Science, Volume 35, Issue 1, January 2026.
Abstract The histamine H3 receptor (H3R) is a class A G protein‐coupled receptor (GPCR) that regulates neurotransmitter release in the central nervous system. Although structures of H3R in both inactive and active states have been elucidated, the functional roles of specific residues remain unclear.
Ami Nakajima, Hiroto Kaneko, Kosuke Oyama, Misumi Kuchiji, Ayane Itakura, Chiaki Arai, Mitsunori Shiroishi   +6 more
wiley   +1 more source

Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists.

Proceedings of the National Academy of Sciences of the United States of America, 2004
P. Freddolino, M. Kalani, N. Vaidehi, Wely B. Floriano, Spencer Hall, R. Trabanino, V. Kam, W. Goddard   +7 more
semanticscholar   +1 more source

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION Repurposing Food and Drug Administration (FDA)‐approved drugs could accelerate treatment development for Alzheimer's disease (AD). METHODS Using the MarketScan claims database (2011 to 2020), we applied a trial emulation approach in two base cohorts: (1) individuals with mild cognitive impairment (MCI cohort) and (2) individuals ...
Reina Tonegawa‐Kuji, Ehud Karavani, Michael Danziger, Pengyue Zhang, Yuan Hou, Yadi Zhou, Marina Bykova, Andrew A. Pieper, Michal Rosen‐Zvi, Jeffrey Cummings, Feixiong Cheng   +10 more
wiley   +1 more source

The Comparative Effectiveness of PDE5 Inhibitors and β3 Agonists Versus α-Blockers in Medical Expulsive Therapy for Distal Ureteric Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Ramanah M, Banerjee I, Nunkoo S, Robinson J, Krissheeven M, Banerjee I.   +5 more
europepmc   +1 more source

EFFECTS OF Ca<SUP>2+</SUP> CHANNEL AGONIST AND &beta;<SUB>1</SUB>-ADRENERGIC AGONIST ON ISOLATED RIGHT ATRIA OF SWIM-TRAINED RATS AND CONTROL RATS

, 1992
Seiji Maeda, Takashi Miyauchi, Katsutoshi Goto, Yasuro Sugishita, Mitsuo Matsuda   +4 more
openalex   +2 more sources

Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo

, 2020
Rachel High, Jill M. Danford, Zhaoyue Shi, Christof Karmonik, Thomas J. Kuehl, Erin T. Bird, Rose Khavari   +6 more
openalex   +1 more source

The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation [PDF]

, 1990
Amber Flatt, Julian Crane, G Purdie, Tai C. Kwong, Richard Beasley, C. Burgess   +5 more
openalex   +1 more source

Haemodynamic Changes After Prophylactic Doses of Ephedrine, Phenylephrine, Norepinephrine Versus Placebo During Induction of General Anaesthesia: A Randomised Trial

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 1, January 2026.
ABSTRACT Background Ephedrine, phenylephrine, and norepinephrine are commonly used to manage hypotension during the induction of anaesthesia. The objective of this study was to evaluate whether prophylactic administration of assumed equipotent doses of these vasopressors could maintain systolic arterial blood pressure (SAP) and heart rate (HR) within ...
Gunnar Helge Sjøen, Tor Hugo Hauge, Ragnhild Sørum Falk, Tor Inge Tønnessen, Eldrid Langesæter   +4 more
wiley   +1 more source